Trial Information
The Potential for Oral DIM Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers
Inclusion Criteria:
- Carriers of a mutation in the BRCA1 gene
- Non-carriers of a mutation in the BRCA1 gene who come from a family with a BRCA1
mutation (a family in which at least one individual has tested positive for a BRCA1
mutation)
- Can participate after being free of DIM supplementation for one month
Exclusion Criteria:
- Have a personal history of cancer
- Currently pregnant or breast-feeding
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science
Outcome Measure:
Oral DIM supplementation increases BRCA1 mRNA expression and hence BRCA1 protein in women with a BRCA1 mutation
Outcome Time Frame:
6 months
Safety Issue:
Yes
Principal Investigator
Steven A Narod, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Women's College Research Institute
Authority:
Canada: Ethics Review Committee
Study ID:
2009-015-B
NCT ID:
NCT01022333
Start Date:
July 2009
Completion Date:
December 2010
Related Keywords:
- Breast Cancer
- BRCA1
- breast cancer
- 3,3'-di-indolylmethane
- dietary intervention
- estrogen metabolites
- mRNA expression
- BRCA1 protein
- Estrogen
- Breast Neoplasms